Agenus (AGEN) Reports Q1 Loss, Misses Revenue Estimates

分组1 - Agenus reported a quarterly loss of $3.04 per share, better than the Zacks Consensus Estimate of a loss of $3.58, and an improvement from a loss of $4.40 per share a year ago, indicating an earnings surprise of 15.08% [1] - The company generated revenues of $28.01 million for the quarter ended March 2024, missing the Zacks Consensus Estimate by 31.19%, but showing an increase from $22.9 million in the same quarter last year [1] - Over the last four quarters, Agenus has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [1] 分组2 - Agenus shares have declined approximately 21.8% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [2] - The current consensus EPS estimate for the upcoming quarter is -$2.83 on revenues of $53.23 million, and for the current fiscal year, it is -$8.21 on revenues of $275.36 million [4] - The Medical - Biomedical and Genetics industry, to which Agenus belongs, is currently ranked in the top 30% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [4]